Literature DB >> 1079721

Levodopa-induced myoclonus.

H L Klawans, C Goetz, D Bergen.   

Abstract

Twelve parkinsonian patients on long-term levodopa therapy developed intermittent, myoclonic body jerks. The movements consisted of single unilateral or bilateral abrupt jerks of the extremities and occurred most frequently during sleep. Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide. Levodopa-induced myoclonus may be related to intermittent increases of activity of serotonin in the brain and results from levodopa-induced dysregulation of serotonin activity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1079721     DOI: 10.1001/archneur.1975.00490470075011

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.

Authors:  Sarah Lemieux; Mehrdad Ghassemi; Mandar Jog; Roderick Edwards; Christian Duval
Journal:  Exp Brain Res       Date:  2006-08-30       Impact factor: 1.972

Review 2.  Drug-induced sleep disturbances. Focus on nonpsychotropic medications.

Authors:  M Novak; C M Shapiro
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 3.  Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.

Authors:  Tai N Tran; Trang N N Vo; Karen Frei; Daniel D Truong
Journal:  J Neural Transm (Vienna)       Date:  2018-07-03       Impact factor: 3.575

Review 4.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

5.  Dopaminergic medication unrelated myoclonus is less related to tremor in idiopathic Parkinson's disease.

Authors:  Ayla Sifoglu; Aysegul Gunduz; Gunes Kiziltan; Meral E Kiziltan
Journal:  Neurol Sci       Date:  2016-12-18       Impact factor: 3.307

Review 6.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

Review 7.  Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.

Authors:  Theresa A Zesiewicz; Kelly L Sullivan; Robert A Hauser
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

8.  Myoclonic attacks induced by L-dopa and bromocryptin in Parkinson patients: a sleep EEG study.

Authors:  J Vardi; H Glaubman; J M Rabey; M Streifler
Journal:  J Neurol       Date:  1978-04-14       Impact factor: 4.849

Review 9.  Clinical neurophysiology of Parkinson's disease and parkinsonism.

Authors:  Robert Chen; Alfredo Berardelli; Amitabh Bhattacharya; Matteo Bologna; Kai-Hsiang Stanley Chen; Alfonso Fasano; Rick C Helmich; William D Hutchison; Nitish Kamble; Andrea A Kühn; Antonella Macerollo; Wolf-Julian Neumann; Pramod Kumar Pal; Giulia Paparella; Antonio Suppa; Kaviraja Udupa
Journal:  Clin Neurophysiol Pract       Date:  2022-06-30

Review 10.  Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Authors:  Jean-François Daneault; Benoit Carignan; Abbas F Sadikot; Michel Panisset; Christian Duval
Journal:  BMC Med       Date:  2013-03-20       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.